PROLİPOZOM TEKNOLOJİSİNDEKİ GÜNCEL GELİŞMELER VE UYGULAMALAR

Öz

Amaç: Lipozomlar, ilaç taşıyıcı sistemler arasında en umut verici ve uygulanabilir olanıdır. Ancak, lipozomların fiziksel ve kimyasal stabilite problemleri kullanımlarını sınırlamaktadır. Bu problemlerin üstesinden gelmek için 1986 yılında prolipozomal sistemler geliştirilmiştir. Bu derleme kapsamında prolipozomal ilaç taşıyıcı sistemler ve uygulamaları ile ilgili yapılmış olan bilimsel araştırmalar akademik veri tabanları taranarak sunulmuştur.

Sonuç ve Tartışma: Prolipozomlar etkin madde, suda çözünür taşıyıcı materyal ve fosfolipitlerden oluşan, su veya biyolojik sıvılar ile temas ettiğinde çok katmanlı lipozomal süspansiyon oluşturan toz veya sıvı lipit yapıdaki ürünlerdir. Bu derlemede, ilaç taşıyıcı sistemler olarak kullanılan prolipozomlar hakkında genel bilgiler verilmiştir. Prolipozomların hazırlanmasında kullanılan bileşenler ve özellikleri tanımlanmıştır. Prolipozomların hazırlama teknolojileri, karakterizasyonu ve avantajlarına değinilmiştir. Derlemenin son bölümünde prolipozomların oral, parenteral, pulmoner, transdermal ve mukozal yollardan uygulanmaları ile ilgili çalışmalar özetlenmiştir. Prolipozomlar üstün in vivo etkinlikleri, yüksek stabiliteleri ve endüstriyel boyutta imal edilebilir olmaları nedeniyle umut verici ilaç taşıyıcı sistemlerdir.

Anahtar Kelimeler

• ilaç taşıyıcı sistemler,lipozom,prolipozomlar,stabilite

RECENT DEVELOPMENTS ON PROLIPOSOME TECHNOLOGY AND APPLICATIONS

Öz

Objective: Liposomes are the most promising and feasible carriers among other drug delivery systems. However, physical and chemical stability problems of liposomes limit their use. In order to overcome these problems, proliposomal systems were developed in 1986. Within the scope of this review, scientific researches about proliposomal drug delivery systems and their applications were presented by searching academic databases.

Result and Discussion: Proliposomes are powder or liquid lipid formulations of active agent, water-soluble carrier material and phospholipids, which form a multilamellar liposomal suspension upon contact with water or biological fluids. In this review, general information about proliposomes as drug delivery systems were given. The components used in the preparation of proliposomes and their properties were described. The preparation technologies, characterization and advantages of proliposomes were discussed. In the last part of the review, studies on the administration of proliposomes by oral, parenteral, pulmonary, transdermal and mucosal routes were summarized. Proliposomes are promising drug delivery systems because of their superior in vivo efficacy, high stability and industrial fabricability.

Anahtar Kelimeler

• drug delivery systems,liposome,proliposomes,stability

Kaynakça

1. 1. Kumara, B.C., Parthiban, S., Senthil kumar, G.P., Tamiz Mani, T. (2015). Proliposome: A novel approach to carrier drug delivery system. International Journal of Biopharmaceutics, 6(2), 98-106
2. 2. Shaji, J., & Bhatia, V. (2013). Proliposomes: A brief overview of novel delivery system. Int J Pharm Biosci, 4, 150-160.
3. 3. Sezgin Bayindir, Z., &Yuksel, N. (2015). Provesicles as novel drug delivery systems. Current Pharmaceutical Biotechnology, 16(4), 344-364
4. 4. Moreira, A. R. S. (2015). Development of proliposomes as a vehicle to deliver new molecules with antitumor activity. Faculty of Medicine of University of Porto, Portugal.
5. 5. Nekkanti, V., Venkatesan, N., Betageri, G. (2015). Proliposomes for oral delivery: progress and challenges. Current Pharmaceutical Biotechnology, 16(4), 303-312.
6. 6. Veerapu, G., Gangadharappa, H. V., Nagashubba, B., Balamuralidhara, V. (2014). Review on novel carrier system: liposomes and proliposomes. Drug Delivery Letters, 4(2), 96-109
7. 7. Manani, H., Prajapati, B., Patel, R. (2016). Review of Preliposomes as novel drug delivery system. The Pharma Innovation, 4(3), 61-67
8. 8. Sun, C., Wang, J., Liu, J., Qui, L., Zhang, W., Zhang, L. (2013). Liquid proliposomes of nimodipine drug delivery system: preparation, characterization, and pharmacokinetics. AAPS Pharmscitech, 14(1), 332-338.

9. 9. Patel, G. M., Shelat, P. K., Lalwani, A. N. (2016). QbD based development of proliposome of lopinavir for improved oral bioavailability. European Journal of Pharmaceutical Sciences, 108, 50-61.
10. 10. Xu, H., He, L., Nie, S., Guan, J., Zhang, X., Yang, X., Pan, W. (2009). Optimized preparation of vincopocetine proliposomes by a novel method and in vivo evaluation of its pharmacokinetics in New Zealand rabbits. Journal of Controlled Release, 140(1), 61-68.
11. 11. Janga, K. Y., Jukanti, R., Velpula, A., Sunkavalli, S., Bandari, S., Kandadi, P., Veerareddy, P. R. (2012). Bioavailability enhancement of zaleplon via proliposomes: Role of surface charge. European Journal of Pharmaceutics and Biopharmaceutics, 80(2), 347-357.
12. 12. Yanamandra, S., Venkatesan, N., Kadajji, V. G., Wang, Z., Issar, M., Betageri, G. V. (2014). Proliposomes as drug delivery system to decrease the hepatic first-pass metabolism: case study using a model drug. European Journal of Pharmaceutical Sciences, 64, 26-36
13. 13. Deshmukh, D., Revis, W. R., Betageri G. V. (2008). Improved delivery of cromolyn from oral proliposomal beads. International Journal of Pharmaceutics, 358(1), 128-136.
14. 14. Wang, S., Ye, T., Yang, B., Yi, X., Yao, H. (2013). 7-ethyl-10-hydroxycamptothecin proliposomes with a novel preparation method: optimized formulation, characterization and in vivo evaluation. Drug Development and Industrial Pharmacy, 39(2), 393-401.
15. 15. Elhissi, A., Gill, H., Ahmed, W., Taylor, K. (2011). Vibrating-mesh nebulization of liposomes generated using an ethanol-based proliposome technology. Journal of Liposome Research, 21(2), 173-180.
16. 16. Rojanarat, W., Nakpheng, T., Thawithong, E., Yanyium, N., Srichana, T. (2012). Levofloxacin-proliposomes: opportunities for use in lung tuberculosis. Pharmaceutics, 4(3), 385-412.
17. 17. Jukanti, R., Sheela, S., Bandari, S., Veerareddy, P. R. (2011). Enhanced bioavailability of exemestane via proliposomes based transdermal delivery. Journal of Pharmaceutical Sciences, 100(8), 3208-3222.
18. 18. Ning, M. Y., Guo, Y. Z., Pan, H. Z., Yu, H. M., Gu, Z. W. (2005). Preparation and evaluation of proliposomes containing clotrimazole. Chemical and Pharmaceutical Bulletin, 53(6), 620-624.
19. 19. Ahn, B. N., Kim, S. K., Shim, C. K. (1995). Proliposomes as an intranasal dosage form for the sustained delivery of propranolol. Journal of Controlled Release, 34(3), 203-210.
20. 20. Song, K. H., Chung, S. J., Shim, C. K. (2002). Preparation and evaluation of proliposomes containing salmon calcitonin. Journal of Controlled Release, 84(1), 27-37.
21. 21. Song, K. H., Chung, S. J., Shim, C. K. (2005). Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts. Journal of Controlled Release, 106(3), 298-308.
22. 22. Potluri, P., & Betageri, G. V. (2006). Mixed-micellar proliposomal systems for enhanced oral delivery of progesterone. Drug Delivery, 13(3), 227-232.
23. 23. Yan-yu, X., Yun-mei, S., Zhi-peng, C., Qi-neng, P. (2006). Preparation of slymarin proliposome: a new way to increase oral bioavailability of slymarin in beagle dogs. International Journal of Pharmaceutics, 319(1), 162-168.
24. 24. Hiremath, P. S., Soppimath, K. S., Betageri, G. V. (2009). Proliposomes of exemestane for improved oral delivery: formulation amd in vitro evaluation using PAMPA, Caco-2 and rat intestine. International Journal of Pharmaceutics, 380(1), 96-104.
25. 25. Chu, C., Tong, S. S., Xu, Y., Wang, L., Fu, M., Ge, Y. R., Xu, X. M. (2011). Proliposomes for oral delivery of dehidrosilymarin: preparation and evaluation in vitro and in vivo, Acta Pharmacologica Sinica, 32(7), 973-980.
26. 26. Bobbala, S. K. R., Veerareddy, P. R. (2012). Formulation, evaluation, and pharmacokinetics of isradipine proliposomes for oral delivery. Journal of Liposome Research, 22(4), 285-294.
27. 27. Velpula, A., Jukanti, R., Janga, K. Y., Sunkavalli, S., Bandari, S., Kandadi, P., Veerareddy, P. R. (2013). Proliposome powders for enhanced intestinal absorption and bioavailability of raloxifene hydrochloride: effect of surface charge. Drug Development and Industrial Pharmacy, 39(12), 1895-1906.
28. 28. Nekkanti, V., Venkatesan, N., Wang, Z., Betageri, G. V. (2015). Improved oral bioavailability of valsartan using proliposomes: design, characterization and in vio pharmacokinetics. Drug Development and Indutrial Pharmacy, 41(12), 2077-2088.
29. 29. Ren, J., Fang, Z., Jiang, L., Du, Q. (2017). Quercetin-containing self-assemble proliposome preparation and evaluation. Journal of Liposome Research, 27(4), 335-342.
30. 30. Zhao, L., Wei, Y., Li, W., Liu, Y., Wang, Y., Zhong, X., Yu, Y. (2011). Solid dispersion and effervescent techniques used to prepare docetaxel liposomes for lung-targeted delivery system: in vitro and in vivo evaluation. Journal of Drug Targeting, 19(3), 171-178.
31. 31. Rojanarat, W., Changsan, N., Tawithong, E., Pinsuwan, S., Chan, H. K., Srichana, T. (2011). Isoniazid proliposome powders for inhalation-prepartion, characterization and cell culture studies. International journal of Molecular Sciences, 12(7), 4414-4434.
32. 32. Rojanarat, W., Nakpheng, T., Thawithong, E., Yanyium, N., Srichan, T. (2012). Inhaled pyrazinamide proliposome for targeting alveolar macrophaged. Drug Delivery, 19(7), 334-345.
33. 33. Patil-Gadhe, A., Pokharkar, V. (2014). Single step spray drying method to develop proliposomes for inhalation: a systematic study based on quality by design approach. Pulmonary Pharmacology & Therapeutics, 27(2), 197-207.
34. 34. Katare, O. P., Vyasx, S. P., Dixit, V. K. (1995). Enhanced in vivo performance of liposomal indomethacin derived from effervescent granüle based proliposomes. Journal of microencapsulation, 12(5), 487-493.
35. 35. Lee, H. J., Ahn, B. N., Yoon, E. J., Paik, W. H., Shim, C. K., Lee, M. G. (1995). Pharmacokinetics and tissue distribution of adriamycin and adriamycinol after intravenous administration of asriamycin-loaded neutral proliposomes to rats. International Journal of Pharmaceutics, 121(1), 1-10.
36. 36. Lee, H. J., Ahn, B. N., Paik, W. H., Shim, C. K., Lee, M. G. (1996). Inverse targeting of reticuloendothelial system-rich organs after intravenous administration of adriamycin-loaded neutral proliposomes containing poloxamer 407 to rats. International Journal of Pharmaceutics. 131(1), 91-96.
37. 37. Junping, W., Maitani, Y., Takayama, K., Nagai, T. (2000). In vivo evaluation of doxorubicin carried with long circulating and remote loading proliposome. International Journal of Pharmaceutics, 203(1), 61-69.
38. 38. Fei, X., Chen, X., Liang, G., Yue-Jian, C., Hao, W., Ning, G., Jia-Bi, Z. (2009). Preparation, characterization, and biodistribution of breviscapine proliposomes in heart. Journal of Drug Targeting, 17(5), 408-414.
39. 39. Jung, B. H., Chung, B. C., Chung, S. J., Lee, M. H., Shim, C. K. (2000). Prolonged delivery of nicotine in rats via nasal administration of proliposomes. Journal of Controlled Release, 66(1), 73-79.
40. 40. Deo, M. R., Sant, V. P., Parekh, S. R., Khopade, A. J., Banakar, U. V. (1997). Proliposome- based transdermal delivery of levonorgestrel. Journal of Biomaterials Applications, 12(1), 77-88.
41. 41. Parthiban, S., Senthil Kumar, G. P. (2016). Development of Proliposomal Gel Containing Glipizide for Better Anti Diabetic Effect. American Journal of PharmTech Research, 6(4), 504-518.
42. 42. Vure, P., Saritha, T., Prakash, D., Triveni, C. (2014). Pro-Vesicular (PV)-Based gel for the topical delivery of Naproxen: Preparation, characterization and in vivo evaluation. Asian Journal of Pharmaceutical and Clinical Research, 7(1), 195-200.
43. 43. Bandari, S., Gangishetty, S., Eedara, B. B., Jukanti, R., Veerareddy, P. R. (2013). Proliposomes of lisinopril dihydrate for transdermal delivery: Formulation aspects and evaluation. Korean Journal of Chemical Engineering, 30(8), 1659-1666.